COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

179 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-22

Study Completion Date

2021-08-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study of COVID-19 seroprevalence in precarious population living in shelters of Samusocial de Paris and in staff working in these centers during COVID-19 epidemic.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Level of Immunity, Neutralization of the COVID-19 Virus and Reinfections in Residents of 2 Migrant Workers' Residences

NCT04932837

SARS-COV-2

WITHDRAWN

Study of COVID-19 Outbreak in Hospital Departments of Bamako, Mali

NCT04710316

Covid19

COMPLETED NA

COVID-19 Surveillance in Rural Mozambique for Prompt and Effective Response

NCT05228639

COVID-19

COMPLETED

Effectiveness of Vaccination Against COVID-19 in Brazil: Case-Control Study

NCT05621928

COVID-19 Vaccines

ACTIVE_NOT_RECRUITING

Effectiveness of Permethrin Impregnated Underwear in Preventing Louse Proliferation in Infected Homeless

NCT01287663

Body's Louses

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After emergence of a new coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV2) responsible for a cluster of respiratory infection at Wuhan, China, on January, 7th 2020, first cases were diagnosed in France in January 24th 2020.

Health care components of Samusocial de Paris (Lits Haltes Soins Santé (LHSS)) were created in 2006. They provide medical care for homeless people and people in social distress not needing an hospitalization. Sometimes there are 3 persons in a bedroom.

In december 2018, a special shelter for isolated women or women in precarious situations opened.

Because of the living conditions in these centers and the difficulty for these populations to respect social distancing and hygiene recommendations.

A first case of COVID-19 was identified on March 8th 2020 in one of these healthcare centers. Other cases were detected in the same center, then in another center on March 16th, then in the dormitory of the women shelter on March 30th.

A recent study showed an important prevalence of SARS-COV2 in residents of a homeless shelter in Boston (36%), most of them were asymptomatic.

Seroprevalence studies are done in general population or in health care workers, but don't include vulnerable people.

It seemed important to us to describe the epidemic in these centers and to study COVID-19 seroprevalence in these particular populations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-COV2 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

hosted in the center and HCWs at the epidemic period

people hosted in the health care or in the women center and health care workers working in one these centers during the epidemic time.

People with initial positive SARS-COV2 serology will have a second blood test to mesure atibodies kinetic

blood test for SARS-COV2 serology

Intervention Type DIAGNOSTIC_TEST

each person who will accept to participate will have a bood test for a SARS-COV2 serology

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood test for SARS-COV2 serology

each person who will accept to participate will have a bood test for a SARS-COV2 serology

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* to have been hosted or working in one the three centers (LHSS Ridder-Plaisance or Saint Michel or Halte femmes) between march and may 2020
* to be aged 18 y or more
* to be able to give an informed consent

Exclusion Criteria

* people who refuse to participate
* not being able to give an informed consent
* Person subject to a legal protection measure (safeguard of justice, curatorship or guardianship)
* Person who does not understand the information provided on how to carry out the research
* Obstacle to venous sampling

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes